Gastroparesis

Current Opinion in Gastroenterology

Volumn 28, Issue 6, 2012, Pages 621-628

  Hasler, William L ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

diabetes mellitus; electrical stimulation; gastric emptying; nausea and vomiting

Indexed keywords

ACOTIAMIDE; APREPITANT; AZITHROMYCIN; DOMPERIDONE; ERYTHROMYCIN; METOCLOPRAMIDE; MIRTAZAPINE; NARONAPRIDE; PRUCALOPRIDE; PYRIDOSTIGMINE; THIETHYLPERAZINE; VELUSETRAG;

ANXIETY; CELIAC ARTERY STENOSIS; CHAGAS DISEASE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DYSPEPSIA; EATING DISORDER; ELECTRODE; ENDOCRINE DISEASE; ENDOSCOPIC SURGERY; GLYCEMIC CONTROL; HEART ATRIUM ARRHYTHMIA; HISTOLOGY; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; IDIOPATHIC DISEASE; JEJUNOSTOMY TUBE; NAUSEA; NAUSEA AND VOMITING; NERVE CELL; NEUROLOGIC DISEASE; NEUROPATHY; NUTRITIONAL DEFICIENCY; PATHOGENESIS; PATHOPHYSIOLOGY; PREGNANCY; RADIOFREQUENCY ABLATION; REVIEW; SATIETY; SEX DIFFERENCE; SIDE EFFECT; SMOOTH MUSCLE CONTRACTILITY; STOMACH; STOMACH EMPTYING; STOMACH MUSCLE; STOMACH PAIN; STOMACH PARESIS; STOMACH PH; SUDDEN DEATH; SYSTEMATIC REVIEW (TOPIC); TARDIVE DYSKINESIA; TOTAL PARENTERAL NUTRITION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIEMETICS; BREATH TESTS; DIABETES COMPLICATIONS; DIET THERAPY; GASTRIC EMPTYING; GASTROINTESTINAL AGENTS; GASTROPARESIS; GHRELIN; HUMANS; RADIONUCLIDE IMAGING; STOMACH;

EID: 84868360779     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328358d619     Document Type: Review

References (94)

1. Jung HK, Choung RS, Locke GR, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009; 136:1225-1233.
2. Rey E, Choung RS, Schleck CD, et al. Prevalence of hidden gastroparesis in the community: the gastroparesis 'iceberg'. J Neurogastroenterol Motil 2012; 18:34-42.
3. Hasler WL, Wilson LA, Parkman HP, et al. Bloating in gastroparesis: severity, impact, and associated factors. Am J Gastroenterol 2011; 106:1492-1502.
4. Parkman HP, Yates KP, Hasler WL, et al. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology 2011; 141:486-498.
5. Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptomonset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 2011; 140:101-115.
6. Revicki DA, Camilleri M, Kuo B, et al. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol Motil 2012; 24:456-463.
7. Kofod-Andersen K, Tarnow L. Prevalence of gastroparesis-related symptoms in an unselected cohort of patients with Type 1 diabetes. J Diab Comp 2012; 26:89-93.
8. Choung RS, Locke GR, Schleck CD, et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012; 107:82-88.
9. Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 2011; 9:1056-1064.
10. Boaz M, Kislov J, Dickman R, Wainstein J. Obesity and symptoms suggestive of gastroparesis in patients with type 2 diabetes and neuropathy. J Diab Comp 2011; 25:325-328.
11. Welsch T, Borm M, Degrate L, et al. Evaluation of the International Study Group of Pancreatic Surgery definition of delayed gastric emptying after pancreatoduodenectomy in a high-volume centre. Br J Surg 2010; 97:1043-1050.
12. Raviv Y, D'Ovidio F, Pierre A, et al. Prevalence of gastroparesis before and after lung transplantation and its association with lung allograft outcomes. Clin Tranplant 2012; 26:133-142.
13. Rodriguez L, Irani K, Jiang H, Goldstein AM. Clinical presentation, response to therapy, and outcome of gastroparesis in children. J Pediatr Gastroenterol Nutr 2012; 55:185-190.
14. Grover M, Farrugia G, Lurken MS, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology 2011; 140:1575-1585.
15. Grover M, Bernard CE, Pasricha PJ, et al. Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol Motil 2012; 24:531-539.
16. Selim MM, Wendelschafer-Crabb G, Redmon JB, et al. Gastric mucosal nerve density: a biomarker for diabetic autonomic neuropathy? Neurology 2010; 75:973-981.
17. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008; 103:753-763.
18. Lee A, Wilding G, Kuo B. Variable abnormal physiological motility in the proximal upper gastrointestinal tract in gastroparesis. Neurogastroenterol Motil. (In press).
19. Kuo B, Maneerattanaporn M, Lee AA, et al. Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. Dig Dis Sci 2011; 56:2928-2938.
20. Rao SS, Mysore K, Attaluri A, Valestin J. Diagnostic utility of wireless motility capsule in gastrointestinal dysmotility. J Clin Gastroenterol 2011; 45:684-690.
21. Perri F, Bellini M, Portincasa P, et al. 13C-octanoic acid breath test (OBT) with a new test meal (EXPIROGer): toward standardization for testing gastric emptying of solids. Dig Liver Dis 2010; 42:549-553.
22. Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 2011; 9:567-576.
23. Bharucha AE, Camilleri M, Forstrom L, Zinsmeister AR. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol 2009; 70:415-420.
24. Pasricha PJ, Yates KP, Tonascia J, et al. Outcomes and predictors of improvement in patients with gastroparesis followed prospectively for 48 weeks (abstract). Gastroenterology 2012; 142:1088.
25. Pasricha PJ, Unalp A, Yenokyan G, et al. Towards a wellness index for motility disorders: the use of desirability functions to evaluate health status in patients with gastroparesis (abstract). Gastroenterology 2012; 142:Tu1486.
26. O'Grady G, Angeli TR, Du P, et al. Abnormal initiation and conduction of slowwave activity in gastroparesis, defined by high-resolution electrical mapping. Gastroenterology. (In press). This careful assessment of multichannel gastric electrical activity provides important insight into conduction defects in gastroparesis that may form the basis for future investigations into therapies that modify electrophysiologic function in this condition. 27. Anaparthy R, Pehlivanov N, Grady J, et al. Gastroparesis and gastroparesislike syndrome: response to therapy and its predictors. Dig Dis Sci 2009; 54:1003-1010.
27. Ramzan Z, Duffy F, Gomez J, et al. Continuous glucose monitoring in gastroparesis. Dig Dis Sci 2011; 56:2646-2655.
28. Bharucha AE, Basu A, Veil EB, et al. Effect of improving glycemic control on gastric emptying in patients with poorly controlled type 2 diabetes mellitus (abstract). Gastroenterology 2012; 142:Tu1459.
29. Sharma D, Morrison G, Joseph F, et al. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis. Diabetologia 2011; 54:2768-2770.
30. Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Exp Rev Endocrinol Metab 2010; 5:653-662.
31. Chini P, Toskes PP, Waseem S, et al. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand J Gastroenterol 2012; 47:422-427.
32. Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol 2008; 6:726-733.
33. Wang D, Parkman HP, Jacobs MR, et al. DNA microarray SNP associations with clinical efficacy and side effects of domperidone treatment for gastroparesis. J Biomed Inform 2012; 45:316-322.
34. Kawamura E, Enomoto M, Kotani K, et al. Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis. Dig Dis Sci 2012; 57:1510-1516.
35. Wo JM, Ejskjaer N, Hellstrom PM, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomitingYrandomised clinical study subset data. Aliment Pharmacol Ther 2011; 33:679-688.
36. McCallum RW, Wo JM, Venuti RP, et al. TZP-102, ghrelin agonist phase 2 data: the improvement in symptoms of gastroparesis (nausea, early satiety, bloating and abdominal pain) significantly correlated with patient rating of overall treatment effect (abstract). Gastroenterology 2011; 140:Tu1365.
37. Coleski R, Anderson MA, Hasler WL. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Dig Dis Sci 2009; 54:2634-2642.
38. Rodriquez L, Rosen R, Manfredi M, Nurko S. Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study. Gastrointest Endosc 2012; 75:302-309.
39. McCallum RW, Lin Z, Forster J, et al. Gastric electrical stimulation improves ouvn1mes of patients with gastroparesis for up to 10 years. ClinGastroenterol Hepatol 2010; 9:314-319.
40. McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 2010; 8:947-954.
41. Hou Q, Lin Z, Mayo MS, et al. Is symptom relief associated with reduction in gastric retention after gastric electrical stimulation treatment in patients with gastroparesis? A sensitivity analysis with logistic regression models. Neurogastroenterol Motil. (In press).
42. Lin Z, Sarosiek I, Forster J, et al. Two-channel gastric pacing in patients with diabetic gastroparesis. Neurogastroenterol Motil 2011; 23:912-e396.
43. Abell TL, Johnson WD, Kedar A, et al. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc 2011; 74:496-503.
44. Deb S, Tang SJ, Abell TL, et al. An endoscopic wireless gastrostimulator (with video). Gastrointest Endosc 2012; 75:411-415.
45. Hibbard ML, Dunst CM, Swanstrom LL. Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement. J Gastrointest Surg 2011; 15:1513-1519.
46. Hasler WL, Parkman HP, Wilson L, et al. Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis. Am J Gastroenterol 2010; 105:2357-2367.
47. Pasricha PJ, Nguyen LA, Snape WJ, et al. Changes in quality of life and symptoms in a large cohort of patients with gastroparesis followed prospectively for 48 weeks (abstract). Gastroenterology 2010; 138:1069.
48. Jung HK, Choung RS, Locke GR, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology 2009; 136:1225-1233.
49. Rey E, Choung RS, Schleck CD, et al. Prevalence of hidden gastroparesis in the community: the gastroparesis 'iceberg'. J Neurogastroenterol Motil 2012; 18:34-42.
50. Hasler WL, Wilson LA, Parkman HP, et al. Bloating in gastroparesis: severity, impact, and associated factors. Am J Gastroenterol 2011; 106:1492-1502.
51. Parkman HP, Yates KP, Hasler WL, et al. Dietary intake and nutritional deficiencies in patients with diabetic or idiopathic gastroparesis. Gastroenterology 2011; 141:486-498.
52. Parkman HP, Yates K, Hasler WL, et al. Clinical features of idiopathic gastroparesis vary with sex, body mass, symptomonset, delay in gastric emptying, and gastroparesis severity. Gastroenterology 2011; 140:101-115.
53. Revicki DA, Camilleri M, Kuo B, et al. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol Motil 2012; 24:456-463.
54. Kofod-Andersen K, Tarnow L. Prevalence of gastroparesis-related symptoms in an unselected cohort of patients with Type 1 diabetes. J Diab Comp 2012; 26:89-93.
55. Choung RS, Locke GR, Schleck CD, et al. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population. Am J Gastroenterol 2012; 107:82-88.
56. Parkman HP, Yates K, Hasler WL, et al. Similarities and differences between diabetic and idiopathic gastroparesis. Clin Gastroenterol Hepatol 2011; 9:1056-1064.
57. Boaz M, Kislov J, Dickman R, Wainstein J. Obesity and symptoms suggestive of gastroparesis in patients with type 2 diabetes and neuropathy. J Diab Comp 2011; 25:325-328.
58. Welsch T, Borm M, Degrate L, et al. Evaluation of the International Study Group of Pancreatic Surgery definition of delayed gastric emptying after pancreatoduodenectomy in a high-volume centre. Br J Surg 2010; 97:1043-1050.
59. Raviv Y, D'Ovidio F, Pierre A, et al. Prevalence of gastroparesis before and after lung transplantation and its association with lung allograft outcomes. Clin Tranplant 2012; 26:133-142.
60. Rodriguez L, Irani K, Jiang H, Goldstein AM. Clinical presentation, response to therapy, and outcome of gastroparesis in children. J Pediatr Gastroenterol Nutr 2012; 55:185-190.
61. Grover M, Farrugia G, Lurken MS, et al. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology 2011; 140:1575-1585.
62. Grover M, Bernard CE, Pasricha PJ, et al. Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol Motil 2012; 24:531-539.
63. Selim MM, Wendelschafer-Crabb G, Redmon JB, et al. Gastric mucosal nerve density: a biomarker for diabetic autonomic neuropathy? Neurology 2010; 75:973-981.
64. Abell TL, Camilleri M, Donohoe K, et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Am J Gastroenterol 2008; 103:753-763.
65. Lee A, Wilding G, Kuo B. Variable abnormal physiological motility in the proximal upper gastrointestinal tract in gastroparesis. Neurogastroenterol Motil. (In press).
66. Kuo B, Maneerattanaporn M, Lee AA, et al. Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. Dig Dis Sci 2011; 56:2928-2938.
67. Rao SS, Mysore K, Attaluri A, Valestin J. Diagnostic utility of wireless motility capsule in gastrointestinal dysmotility. J Clin Gastroenterol 2011; 45:684-690.
68. Perri F, Bellini M, Portincasa P, et al. 13C-octanoic acid breath test (OBT) with a new test meal (EXPIROGer): toward standardization for testing gastric emptying of solids. Dig Liver Dis 2010; 42:549-553.
69. Pasricha PJ, Colvin R, Yates K, et al. Characteristics of patients with chronic unexplained nausea and vomiting and normal gastric emptying. Clin Gastroenterol Hepatol 2011; 9:567-576.
70. Bharucha AE, Camilleri M, Forstrom L, Zinsmeister AR. Relationship between clinical features and gastric emptying disturbances in diabetes mellitus. Clin Endocrinol 2009; 70:415-420.
71. Pasricha PJ, Yates KP, Tonascia J, et al. Outcomes and predictors of improvement in patients with gastroparesis followed prospectively for 48 weeks (abstract). Gastroenterology 2012; 142:1088.
72. Pasricha PJ, Unalp A, Yenokyan G, et al. Towards a wellness index for motility disorders: the use of desirability functions to evaluate health status in patients with gastroparesis (abstract). Gastroenterology 2012; 142:Tu1486.
73. O'Grady G, Angeli TR, Du P, et al. Abnormal initiation and conduction of slowwave activity in gastroparesis, defined by high-resolution electrical mapping. Gastroenterology. (In press). This careful assessment of multichannel gastric electrical activity provides important insight into conduction defects in gastroparesis that may form the basis for future investigations into therapies that modify electrophysiologic function in this condition. 27. Anaparthy R, Pehlivanov N, Grady J, et al. Gastroparesis and gastroparesislike syndrome: response to therapy and its predictors. Dig Dis Sci 2009; 54:1003-1010.
74. Ramzan Z, Duffy F, Gomez J, et al. Continuous glucose monitoring in gastroparesis. Dig Dis Sci 2011; 56:2646-2655.
75. Bharucha AE, Basu A, Veil EB, et al. Effect of improving glycemic control on gastric emptying in patients with poorly controlled type 2 diabetes mellitus (abstract). Gastroenterology 2012; 142:Tu1459.
76. Sharma D, Morrison G, Joseph F, et al. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis. Diabetologia 2011; 54:2768-2770.
77. Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Exp Rev Endocrinol Metab 2010; 5:653-662.
78. Chini P, Toskes PP, Waseem S, et al. Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility. Scand J Gastroenterol 2012; 47:422-427.
79. Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol 2008; 6:726-733.
80. Wang D, Parkman HP, Jacobs MR, et al. DNA microarray SNP associations with clinical efficacy and side effects of domperidone treatment for gastroparesis. J Biomed Inform 2012; 45:316-322.
81. Kawamura E, Enomoto M, Kotani K, et al. Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis. Dig Dis Sci 2012; 57:1510-1516.
82. Wo JM, Ejskjaer N, Hellstrom PM, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomitingYrandomised clinical study subset data. Aliment Pharmacol Ther 2011; 33:679-688.
83. McCallum RW, Wo JM, Venuti RP, et al. TZP-102, ghrelin agonist phase 2 data: the improvement in symptoms of gastroparesis (nausea, early satiety, bloating and abdominal pain) significantly correlated with patient rating of overall treatment effect (abstract). Gastroenterology 2011; 140:Tu1365.
84. Coleski R, Anderson MA, Hasler WL. Factors associated with symptom response to pyloric injection of botulinum toxin in a large series of gastroparesis patients. Dig Dis Sci 2009; 54:2634-2642.
85. Rodriquez L, Rosen R, Manfredi M, Nurko S. Endoscopic intrapyloric injection of botulinum toxin A in the treatment of children with gastroparesis: a retrospective, open-label study. Gastrointest Endosc 2012; 75:302-309.
86. McCallum RW, Lin Z, Forster J, et al. Gastric electrical stimulation improves ouvn1mes of patients with gastroparesis for up to 10 years. ClinGastroenterol Hepatol 2010; 9:314-319.
87. McCallum RW, Snape W, Brody F, et al. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin Gastroenterol Hepatol 2010; 8:947-954.
88. Hou Q, Lin Z, Mayo MS, et al. Is symptom relief associated with reduction in gastric retention after gastric electrical stimulation treatment in patients with gastroparesis? A sensitivity analysis with logistic regression models. Neurogastroenterol Motil. (In press).
89. Lin Z, Sarosiek I, Forster J, et al. Two-channel gastric pacing in patients with diabetic gastroparesis. Neurogastroenterol Motil 2011; 23:912-e396.
90. Abell TL, Johnson WD, Kedar A, et al. A double-masked, randomized, placebo-controlled trial of temporary endoscopic mucosal gastric electrical stimulation for gastroparesis. Gastrointest Endosc 2011; 74:496-503.
91. Deb S, Tang SJ, Abell TL, et al. An endoscopic wireless gastrostimulator (with video). Gastrointest Endosc 2012; 75:411-415.
92. Hibbard ML, Dunst CM, Swanstrom LL. Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement. J Gastrointest Surg 2011; 15:1513-1519.
93. Hasler WL, Parkman HP, Wilson L, et al. Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis. Am J Gastroenterol 2010; 105:2357-2367.
94. Pasricha PJ, Nguyen LA, Snape WJ, et al. Changes in quality of life and symptoms in a large cohort of patients with gastroparesis followed prospectively for 48 weeks (abstract). Gastroenterology 2010; 138:1069.